US2017051312A1PendingUtilityA1

Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

Assignee: CHARPENTIER EMMANUELLEPriority: May 25, 2012Filed: Apr 4, 2016Published: Feb 23, 2017
Est. expiryMay 25, 2032(~5.8 yrs left)· nominal 20-yr term from priority
H10P 14/6512H10P 14/20A61P 43/00A61P 31/00A61P 31/04A61P 35/00A61P 31/12C12Q 1/686C12N 15/63C12N 2800/80C12N 15/113C12N 15/102C12N 2310/3519C12N 15/111C12N 2310/13C07K 2319/71C12N 15/907C12N 9/22C12N 2310/11C12N 15/90C12N 15/746C12Y 301/04A01H 6/4684A61K 48/00C12N 2310/33C12N 2310/531C12N 15/902C12N 2310/31C12N 2310/14C12N 15/70C07K 2319/85A61K 38/465C12N 5/10C12N 2310/32C12N 2310/20A01K 67/027H10H 20/0137C12N 9/226Y02A50/30
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

Claims

exact text as granted — not AI-modified
1 .- 155 . (canceled) 
     
     
         156 . A method of cleaving a nucleic acid comprising contacting a target DNA molecule having a target sequence with
 a) a Cas9 protein; and   b) a single molecule DNA-targeting RNA comprising
 i) a targeter-RNA that hybridizes with the target sequence, and 
 ii) an activator-RNA that hybridizes with the targeter-RNA to form a double-stranded RNA duplex of a protein-binding segment, wherein the activator-RNA comprises the nucleotide sequence set forth as SEQ ID NO: 1347, 
 wherein the activator-RNA and the targeter-RNA are covalently linked to one another with intervening nucleotides, 
   
       wherein said contacting is in vitro outside of a cell, 
       wherein the single molecule DNA-targeting RNA forms a complex with the Cas9 protein, 
       whereby the single molecule DNA-targeting RNA targets the target sequence, and the Cas9 protein cleaves the target DNA molecule. 
     
     
         157 . The method of  claim 156 , wherein said double-stranded RNA duplex has a length of from 8 base pairs (bp) to 30 bp.

Join the waitlist — get patent alerts

Track US2017051312A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.